Clinical importance of serum secreted clusterin in predicting invasive breast cancer and treatment responses

Figures & data

Table 1. Clinicopathologic characteristics of patients with invasive breast cancer

Characteristic	Static group (n = 1998)	Dynamic group (n = 650)
		Surgery (n = 160)	Chemotherapy (n = 490)
Age (years)
<50	923	73	178
≥50	1075	87	312
Tumor size (Diameter)
≤ 2 cm	288	18	36
>2 cm≤5 cm	1350	106	370
>5 cm	360	36	84
Histopathological Grades
G1	230	19	61
G2	1478	121	348
G3	290	20	81
Clinical Stages
I	208	14	41
II	970	80	231
III	820	66	218
Lymph metastasis
Yes	1180	94	316
No	818	66	174
Distant metastasis
Yes	115	19	64
No	1883	141	426
Subtype
Luminal A	320	21	59
Luminal B	1111	92	293
HER2 (+)	211	16	48
Triple negative	356	31	90
Menopause
Yes	798	70	216
No	1200	90	274
ER
Positive(+)	1313	102	322
Negative(-)	685	58	168
PR
Positive(+)	1017	91	286
Negative(-)	981	69	204

Table 2. Relationship between sCLU levels and clinicopathological factors in 1998 IBC patients

Group	sCLU level (μg/mL)	P-value
Age (years)		0.089
<50	78.9 ± 11.6
≥50	81.3 ± 11.7
Tumor size		0.163
≤ 2 cm	77.7 ± 10.3
>2 cm	80.4 ± 11.5
Grade		0.251
G1-G1	78.3 ± 12.4
G3	80.6 ± 11.8
Clinical Stages		<0.0001
I–II	56.4 ± 12.8
III	92.6 ± 13.8
Lymph metastasis		<0.0001
Yes	89.7 ± 12.6
No	60.4 ± 11.8
Distant metastasis		0.173
Yes	82.6 ± 13.5
No	78.4 ± 12.7
Subtype		0.494
Luminal A	78.5 ± 12.7
Luminal B	77.6 ± 13.1
HER2 (+)	81.6 ± 13.6
Triple negative	82.6 ± 12.7
Menopause		0.560
Yes	79.0 ± 12.5
No	79.8 ± 12.2
ER		0.137
Positive(+)	81.6 ± 12.5
Negative(-)	78.4 ± 12.5
PR		0.382
Positive(+)	78.4 ± 11.8
Negative(-)	80.9 ± 12.6

Figure 1. Serum sCLU levels in IBC and controls. Serum sCLU yielded an AUC value of 0.87 in distinguishing IBC from controls

Figure 2. Kaplan-Meier survival curves. Percent survival rate was stratified by serum sCLU level. A, overall survival of patients;B, progression-free survival

Figure 3. ELISA detection of serum sCLU levels. A, Surgical patients; B, Chemotherapy patients